HRT and Breast Cancer Risk (2026): The Real Numbers

HRT doesn't cause most breast cancers, but combined HRT - estrogen with a progestogen - slightly increases the chance of being diagnosed, and the increase grows the longer it's used. Estrogen-only HRT carries little or no added risk, and low-dose vaginal estrogen carries none that studies have detected.

Breast cancer is the reason many women never start hormone therapy, and the reason many stop it early. That fear is understandable. For two decades it was printed in a black box on every package. But fear is a poor guide to a decision, and "HRT causes breast cancer" is too blunt to be useful. Which hormones, for how long, starting when, and compared with what? Those details change the answer by a factor of ten.

This guide gives you the numbers, in absolute terms, from the two bodies of evidence that matter most: the Women's Health Initiative randomized trials and the 2019 Lancet meta-analysis of 58 studies. We explain what each one can and can't tell you, where they disagree, and how to use them in a real conversation with your clinician.

HRT and breast cancer at a glance

Because the FDA changed the label. In November 2025 it asked manufacturers to remove breast cancer, heart disease and dementia from the boxed warning on menopausal hormone therapy. It approved the first six updated labels on February 12, 2026, and three more estradiol patches on October 30, 2026. The breast cancer information stays in the label's warnings section - it moved out of the box, not out of the label.

The change followed an FDA expert panel in July 2025 and a review of the evidence (Pharmacy Times on the February 2026 labels; HHS on the October 2026 approvals). For many women, the most visible effect is that the scariest words on the leaflet are gone. That's prompting a fair question: was the risk overstated all along, or has something been quietly downplayed?

The answer is a bit of both. The original 2002 headlines lumped every woman and every type of hormone together and reported relative risks without context, which overstated the danger for most women. But the risk with combined HRT is real, it is measurable, and it should be part of the decision. Our full explainer on the label change is HRT's black box warning removed.

About 1 in 8 US women will be diagnosed with invasive breast cancer in her lifetime. The American Cancer Society estimates about 321,910 new cases of invasive breast cancer in US women in 2026. Any extra risk from HRT sits on top of this baseline, which rises with age.

Starting with the baseline matters, because an increase only means something when you know what it's increasing. According to the American Cancer Society:

In the 2019 Lancet analysis, women in high-income countries who never used HRT had about a 6.3% chance of being diagnosed with breast cancer between ages 50 and 69. Keep that 6.3 in mind - it's the number the HRT figures below are compared with.

The WHI ran two randomized trials. In the combined trial (estrogen plus a synthetic progestin), women on hormones had about 8 more invasive breast cancers per 10,000 women per year than women on placebo. In the estrogen-alone trial (women without a uterus), the hormone group had fewer breast cancers than placebo - and after 20 years of follow-up, fewer breast cancer deaths.

The WHI is the only large randomized trial of HRT and breast cancer, which is why it carries so much weight. Randomization means the hormone and placebo groups were alike in every other way, so differences can be attributed to the hormones themselves.

What the WHI can't tell you

• The hormones are older types. Most women today use estradiol and, if they need it, micronized progesterone - not conjugated equine estrogens and medroxyprogesterone acetate.
• Participants were older. The average age at enrollment was 63, about a decade past the typical start of menopause.
• Route: everyone took pills; patches and gels weren't studied.

Even with those limits, the WHI's two-trial design gives one of the clearest findings in this field: the progestogen component, not estrogen alone, drives most of the excess breast cancer risk.

The 2019 Lancet meta-analysis pooled 58 studies including more than 100,000 women with breast cancer. For women of average weight who used HRT for five years starting at age 50, it estimated one extra breast cancer between ages 50 and 69 for every 50 users of daily combined HRT, every 70 users of cyclical combined HRT, and every 200 users of estrogen-only HRT. Vaginal estrogen showed no increase.

The Collaborative Group on Hormonal Factors in Breast Cancer reanalysed individual data from 58 epidemiological studies worldwide, with 143,887 women with invasive breast cancer and 424,972 without. It is the largest analysis ever done on this question, and it prompted the UK medicines regulator to issue new guidance (MHRA Drug Safety Update).

The study also found that:

• Risk rose with duration. Ten years of use carried roughly twice the excess risk of five years.
• Some excess risk persisted for more than 10 years after stopping, although it fell after use ended.
• Relative risks were similar whether women started in their 40s or 50s.
• Tablets and patches showed similar risks.

Why the Lancet and WHI disagree on estrogen alone

The Lancet analysis found a small increase with estrogen alone; the WHI randomized trial found a decrease. The most likely reasons are design (observational studies can't fully separate the effect of hormones from the kind of women who choose to take them), the type of estrogen (WHI used conjugated equine estrogens), and the timing of start. Either way, both sources agree that estrogen-only risk is small - and much smaller than the risk with combined therapy.

Relative risk tells you how much a risk changes in percentage terms; absolute risk tells you how many people are actually affected. "HRT raises breast cancer risk by 30%" and "HRT causes about 2 extra cases per 100 women over 20 years" can describe the same data. For decisions, absolute risk is the number that matters.

A worked example using the Lancet figures:

Both numbers are true. The relative figure sounds alarming; the absolute one shows the scale. When a headline gives you only a percentage increase, ask "out of how many?"

Different studies, different frames

You'll see numbers expressed per 10,000 women per year (WHI), per 100 women over 20 years (Lancet), or per 1,000 women over 5 years (UK patient leaflets). They aren't directly comparable, so compare within one source rather than mixing them.

Yes. Across both the WHI trials and the Lancet meta-analysis, estrogen-only HRT carries much less breast cancer risk than estrogen combined with a progestogen. But estrogen-only HRT is only appropriate for women who have had a hysterectomy - with a uterus, estrogen alone raises the risk of endometrial cancer.

This is the single most important distinction in the whole topic. If you've had a hysterectomy, your breast cancer picture on HRT is very different from that of a woman taking combined therapy. If you still have a uterus, you need a progestogen to protect the uterine lining - and the choice of progestogen may matter (next section).

The Menopause Society's 2022 position statement notes that estrogen alone has a more favorable breast profile, while combined therapy's risk appears to rise after about three to five years of use.

Possibly. In the large French E3N cohort, women using estrogen with micronized progesterone had no increase in breast cancer risk (relative risk 1.00), while those using estrogen with synthetic progestins had a 69% higher relative risk (1.69). These findings are observational, so they suggest - but don't prove - that micronized progesterone is gentler on the breast.

Source: Fournier et al., Breast Cancer Research and Treatment, 2008. Most participants used progesterone for relatively short durations, and some later analyses suggest the advantage may narrow with longer use, so it isn't a free pass.

In practice, micronized progesterone (Prometrium and generics) is the most commonly prescribed progestogen in US menopause care today, and many clinicians prefer it partly for this reason. A levonorgestrel IUD is another option for protecting the uterus; its breast data are mixed. Our progesterone guide covers the choices in detail.

No clear difference has been shown. The 2019 Lancet analysis found similar breast cancer risks for oral and transdermal estrogen. Patches and gels do have a real advantage for blood clots and stroke, but not, as far as current evidence shows, for the breast.

This is a common misunderstanding. Transdermal estrogen bypasses the liver, which is why it carries a lower risk of clots than pills. But breast tissue responds to circulating estrogen whichever way it gets into the blood. If breast cancer risk is your main concern, the more important choices are whether you need a progestogen, which one, and for how long - see estrogen patch vs pill for the full comparison.

No increase has been found. Low-dose vaginal estrogen - creams, tablets and rings used for dryness, painful sex and urinary symptoms - wasn't associated with higher breast cancer risk in the Lancet meta-analysis or in large cohort studies, and the UK regulator says low-dose vaginal estrogens do not appear to increase risk.

Very little estrogen reaches the bloodstream at low vaginal doses. That's why medical societies welcomed removing the boxed warning from these products in particular. Women with a history of breast cancer are a special case and should involve their oncologist; see our vaginal estrogen guide.

There's no safe-or-unsafe cutoff. With combined HRT, the excess risk is small in the first few years and grows the longer it's used - the Lancet analysis estimated roughly twice the excess risk for ten years of use as for five. With estrogen alone, the increase over time is much smaller. Guidelines don't set a mandatory stop date; they recommend reviewing the decision at least once a year.

The Menopause Society does not recommend routinely stopping HRT at a particular age, such as 60 or 65. Duration is a personal decision that weighs ongoing symptoms, bone health and individual risk. Some women choose the lowest effective dose; others switch to estrogen-only where possible (after hysterectomy) or to non-hormonal options for hot flashes. See is HRT safe? for the other risks and benefits in the balance.

Risk falls after stopping, but according to the 2019 Lancet analysis some of the excess persists for more than 10 years in women who used HRT for longer than a year. That persistence is one reason the Lancet figures were higher than earlier estimates.

This finding surprised many clinicians when it was published, because earlier studies suggested the excess disappeared within about five years of stopping. It's based on observational data and remains debated, but it's the reason regulators asked prescribers to explain to women that some risk can outlast use. It doesn't mean stopping is pointless - risk is still lower after stopping than during continued use.

Stopping HRT can also bring hot flashes back for about half of women. If that happens, non-hormonal treatments are an option; see how to stop hot flashes.

The Lancet analysis found similar relative risks whether women started HRT at 40-44, 45-49, 50-54 or 55-59. But the absolute numbers depend on the background risk, which rises with age. Women with early or premature menopause are different: replacing hormones until the average age of menopause isn't thought to raise breast cancer risk above that of women who go through menopause naturally around 51.

For women whose periods stop before 40 (premature ovarian insufficiency) or before 45, hormone therapy is generally recommended until around the natural age of menopause, both for symptoms and to protect bones and the heart. The breast cancer data from older women don't straightforwardly apply to them, because they're replacing hormones their bodies would otherwise still be making.

For most women, combined HRT's added risk is in the same range as drinking two or more alcoholic drinks a day and smaller than the risk linked to obesity after menopause. Regular exercise lowers risk by a similar amount.

The UK charity Women's Health Concern, using figures from NICE menopause guidance, illustrates this for women aged 50 to 59 over five years (WHC risk leaflet):

For HRT itself, use the Lancet and WHI figures above. Because these sources use different time frames, the comparison is illustrative rather than exact - but the point holds: HRT is one modest factor among several, and some of the larger ones are within your control.

Other established risk factors

• Age (the biggest single factor)
• Inherited mutations such as BRCA1 and BRCA2
• Family history of breast or ovarian cancer
• Dense breast tissue on mammogram
• Previous chest radiation
• Early first period, late menopause, no pregnancies or a first pregnancy after 30

Often, yes. A family history of breast cancer is not by itself a reason to avoid HRT, according to major menopause societies. It does raise your baseline risk, so the decision deserves a careful conversation - and women with BRCA mutations or very strong family histories should involve a genetics or high-risk breast specialist.

• One relative diagnosed after 50: generally a modest increase in baseline risk; HRT is usually still an option.
• Several relatives, relatives diagnosed young, or ovarian cancer in the family: consider genetic counseling and a formal risk assessment first.
• BRCA carriers who have had their ovaries removed before natural menopause: observational studies suggest short-term HRT until around the average age of menopause doesn't appear to raise breast cancer risk meaningfully, and it protects bones and the heart. This is a specialist decision.

Yes. Keep up with routine screening. The US Preventive Services Task Force recommends mammograms every two years for women aged 40 to 74. Combined HRT can make breast tissue denser on mammograms, which can make them slightly harder to read and lead to more callbacks.

• Tell the imaging center you're on HRT.
• Since September 2024, US mammography reports must tell you whether your breasts are dense; if they are, ask whether additional imaging makes sense for you.
• New lumps, skin changes, nipple discharge or a change in breast shape should be checked promptly whether or not you use HRT.

Source: USPSTF breast cancer screening recommendation (2024).

Systemic HRT is generally not recommended after breast cancer. The randomized HABITS trial was stopped early (results published in 2004) after women with a history of breast cancer who took HRT had more recurrences. Non-hormonal treatments are the usual first choice; low-dose vaginal estrogen may be considered for severe vaginal symptoms with the oncology team's agreement.

Good options exist for survivors. For hot flashes: SNRIs such as venlafaxine, gabapentin, CBT, clinical hypnosis and - with oncology input - newer non-hormonal drugs. Women taking tamoxifen should avoid paroxetine and fluoxetine, which interfere with tamoxifen. See hot flash treatments ranked and the breast cancer section of our vaginal estrogen guide.

The best randomized evidence says no for estrogen alone - the WHI found fewer breast cancer deaths with estrogen alone than placebo after 20 years (30 vs 46 deaths). For combined therapy, the WHI found more diagnoses but no statistically significant difference in breast cancer deaths over 20 years.

Being diagnosed and dying from breast cancer are different outcomes, and studies that only count diagnoses can't tell you about the second. Breast cancer mortality has fallen substantially in the US over recent decades thanks to screening and better treatment, which also affects how these numbers play out today. For the full WHI picture, including heart disease and other outcomes, see is HRT safe?

There's no evidence that compounded "bioidentical" hormones are safer for the breast than FDA-approved products. FDA-approved estradiol and micronized progesterone are themselves bioidentical. Compounded creams and pellets haven't been studied for breast safety, and pellets can produce hormone levels well above the normal range.

Some clinics market compounded hormones as "natural" and therefore lower-risk. Estradiol is estradiol, whatever the pharmacy. The difference with compounded products is uncertainty: doses vary more, and there's no safety data. If breast cancer risk is a concern, an FDA-approved regimen with a known dose is the more conservative choice. See bioidentical hormones explained.

These illustrative examples apply the published averages to three common situations. They're not personal risk predictions - your clinician can estimate your own baseline using validated tools.

The extra breast cancers linked to HRT are mainly hormone-receptor-positive (estrogen-receptor-positive) tumors, which generally respond well to treatment. Combined HRT has also been linked to lobular breast cancer, a type that can be harder to see on mammograms.

The Lancet analysis found the excess risk was concentrated in estrogen-receptor-positive cancers. That fits the biology: these tumors grow in response to hormones. It also explains why women with a history of hormone-receptor-positive breast cancer are generally advised against systemic HRT. Knowing the tumor type doesn't make a diagnosis less serious, but it is part of why breast cancer deaths in the WHI weren't significantly increased with combined therapy.

Yes, in different directions. Estrogen without a progestogen raises endometrial (uterine) cancer risk in women with a uterus, which is why combined therapy exists. Ovarian cancer risk may rise slightly with use. Colorectal cancer was less common with combined HRT in the WHI.

This is why any bleeding after menopause, or unexpected bleeding on HRT, should be checked. More on the whole risk-benefit picture is in is HRT safe?

Because the first results were reported mainly as a relative increase - about 26% more breast cancer - without the absolute numbers, and applied to every woman and every hormone. In absolute terms, the difference was about 8 extra cases per 10,000 women per year, in older women using one specific combination.

After July 2002, HRT use in the US fell sharply, and for many years women and clinicians avoided it even for severe symptoms. Later analyses showed that the trial's average participant was 63, that estrogen alone behaved differently, and that the overall balance looks more favorable for healthy women who start near menopause. The breast cancer finding for combined therapy has held up; the way it was communicated is what changed. Our full history is in the black box warning guide.

Usually not. Breast tenderness or swelling is a common side effect when starting HRT or changing dose, especially in the first few months, and it often settles. It isn't a known early sign of breast cancer. A new lump, skin dimpling, nipple changes or tenderness in one specific spot that doesn't go away should be checked.

If tenderness persists, clinicians often lower the estrogen dose or change the progestogen. Report it rather than stopping on your own - there's usually a simple adjustment.

The FDA removed the breast cancer statement from the boxed warning - the most prominent warning on a drug label - on menopausal hormone therapy products. It did not remove breast cancer information from the label: it remains in the warnings and precautions section. Systemic estrogen-only products keep a boxed warning about endometrial cancer.

Labels are being updated product by product; the first six were approved on February 12, 2026, and three more estradiol patches on October 30, 2026. Not every product's leaflet will look the same yet.

Use the lowest dose that controls your symptoms, use estrogen alone if you've had a hysterectomy, consider micronized progesterone if you need a progestogen, review the decision every year, keep up with mammograms, and work on the lifestyle factors that affect breast cancer risk at least as much as HRT does.

1. Match the regimen to your body: no uterus, no progestogen needed.
2. Discuss the progestogen: micronized progesterone, or a levonorgestrel IUD in some cases.
3. Use the lowest effective dose, and don't increase it for marginal benefit.
4. Review yearly: symptoms, bone health and risk change over time.
5. Screen: mammograms every two years from 40 to 74, more often if advised.
6. Limit alcohol: regular drinking raises breast cancer risk independently of HRT.
7. Stay active and manage weight: post-menopausal obesity is one of the larger modifiable risk factors.
8. Know your family history, and ask about genetic counseling if it's strong.

Systemic HRT is generally avoided by women who have had breast cancer or another estrogen-sensitive cancer, and approached with specialist input by women at very high inherited risk. For most other women, breast cancer risk is one factor to weigh, not an automatic reason to say no.

• Generally avoid systemic HRT: personal history of breast cancer; current suspected breast cancer.
• Specialist input first: BRCA1/2 or other high-risk mutations (unless after risk-reducing surgery, as above), very strong family history, prior atypical hyperplasia or lobular carcinoma in situ.
• Weigh carefully: long planned duration of combined therapy, starting HRT for the first time after 60, high breast density with other risk factors.

Women who can't take HRT have effective alternatives for hot flashes and vaginal symptoms - see every hot flash treatment ranked.

Ask what your personal baseline risk is, how much a specific HRT regimen would change it in absolute numbers, whether you need a progestogen and which one, how long you're likely to use it, and what screening you need.

• What is my estimated breast cancer risk without HRT, given my age and family history?
• How would this regimen change that, in actual numbers?
• Do I need a progestogen? Would micronized progesterone or an IUD suit me?
• What's the lowest dose likely to work for my symptoms?
• How often will we review this, and what would make you suggest stopping?
• Are my breasts dense, and do I need extra imaging?
• Should I see a genetic counselor?

If you'd like to talk this through with a menopause clinician online, compare providers in our online HRT comparison.

• Absolute risk: the chance of something happening, such as 6 in 100.
• Relative risk / hazard ratio: how much a risk changes compared with another group; 1.28 means 28% higher.
• Combined HRT: estrogen plus a progestogen, for women with a uterus.
• Estrogen-only HRT: estrogen without a progestogen, for women without a uterus.
• Continuous vs cyclical: progestogen taken every day vs on some days of each month.
• Micronized progesterone: progesterone identical to the body's own (e.g., Prometrium).
• Synthetic progestin: lab-made progestogens such as medroxyprogesterone acetate.
• Randomized controlled trial: participants are assigned to treatment or placebo by chance, the strongest test of cause and effect.
• Meta-analysis: a combined analysis of many studies.
• WHI: Women's Health Initiative, the largest US randomized trials of HRT.
• Dense breasts: more glandular and fibrous tissue relative to fat, which can hide tumors on mammograms and is itself a risk factor.

We built this guide from the original publications - the WHI trial reports in JAMA (2002, 2004, 2020), the 2019 Lancet meta-analysis, the E3N cohort, American Cancer Society statistics, UK regulator guidance and FDA labeling decisions - checked on November 5, 2026. Where studies disagree, we show both. We state whether each finding comes from a randomized trial or an observational study, and we give absolute numbers wherever the source allows. We don't tell anyone to start or stop a medicine. HRT Women earns commissions from some providers; that doesn't change the evidence or how we report it. See our medical review policy.

HRT's effect on breast cancer is real but smaller and more specific than its reputation. Combined estrogen-progestogen therapy adds a small, duration-dependent risk; estrogen alone adds little or none; vaginal estrogen adds none that studies have found. For most healthy women in their 50s with bothersome symptoms, that risk is one factor in a decision that also includes hot flashes, sleep, bone health and quality of life.

• Ask for absolute numbers, not percentages.
• Know which type you'd be taking - estrogen alone or combined, and which progestogen.
• Use the lowest effective dose and review every year.
• Keep screening, limit alcohol, stay active.
• If you've had breast cancer or carry a high-risk mutation, decide with a specialist.

For the wider picture, read is HRT safe?, what is HRT? and our complete menopause guide.

This article is general information, not medical advice. A licensed clinician should help you weigh the risks and benefits of any treatment for your situation.

• Writing Group for the WHI Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288(3):321-333
• WHI Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA. 2004;291(14):1701-1712
• Chlebowski RT, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the WHI randomized clinical trials. JAMA. 2020;324(4):369-380
• Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk. Lancet. 2019;394:1159-1168
• MHRA Drug Safety Update: HRT and the known increased risk of breast cancer and its persistence after stopping (2019)
• Fournier A, et al. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008
• American Cancer Society: How common is breast cancer? (2026 estimates)
• Women's Health Concern: Understanding the risks of breast cancer
• US Preventive Services Task Force: Breast cancer screening recommendation (2024)
• The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022
• FDA approves labeling changes to six menopausal hormone therapy products (Feb 2026)
• HHS: FDA advances menopause care with hormone therapy labeling updates (Oct 2026)
• Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped. Lancet. 2004;363:453-455.